Comparative Pharmacology
Head-to-head clinical analysis: EMBOLEX versus LOVENOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMBOLEX versus LOVENOX.
EMBOLEX vs LOVENOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Low molecular weight heparin that potentiates antithrombin III, inhibiting factor Xa and factor IIa, thereby preventing thrombus formation.
Low molecular weight heparin (LMWH) that binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin, thereby preventing thrombus formation.
Embolectomy with intra-arterial streptokinase: 250,000 IU loading dose over 30 minutes followed by 100,000 IU/hour for up to 72 hours. Alternatively, mechanical thrombectomy without thrombolytic.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis in abdominal surgery, hip or knee replacement; 30 mg subcutaneously every 12 hours for prophylaxis in medical patients; 0.5 mg/kg subcutaneously once daily for prophylaxis in patients with acute coronary syndrome.
None Documented
None Documented
2-3 hours (terminal half-life in healthy adults); prolonged in hepatic impairment and elderly.
Terminal half-life: 4.5-7 hours after subcutaneous administration; prolonged in renal impairment (up to 16 hours with CrCl <30 mL/min), requiring dose adjustment.
Renal: ~50% (10% as unchanged drug, 40% as inactive metabolites); Biliary/fecal: ~50% (primarily as metabolites).
Renal: 40-60% as active and inactive fragments via glomerular filtration and tubular secretion; biliary/fecal: minimal, <10%.
Category C
Category C
Low Molecular Weight Heparin
Low Molecular Weight Heparin